Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae

Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape

(2016) R. M. Humphries et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012–2014

(2016) James A. Karlowsky et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases

(2015) Krisztina M. Papp-Wallace et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

(2014) Henry Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species

(2012) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009

(2011) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftaroline

(2009) George G. Zhanel et al.   DRUGS